AXL and hepatocellular carcinoma: The incremental effects of R428 on sorafenib-induced growth inhibitory and pro-apoptotic potential are promising features for the development of Axl-inhibitors in the first-line treatment of advanced HCC aiming to prolong progression-free survival before patients face untreatable progression due to liver dysfunction or symptomatic progression.